Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Paycom Software Inc (PAYC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Paycom Software Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223 (market cap $29.60B), while Paycom Software Inc trades at $210.62 (market cap $9.57B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.1× Paycom Software Inc's market cap, and Paycom Software Inc pays a 0.71% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | PAYC | |
|---|---|---|
Market Cap | $29.60B | $9.57B |
Sector | Health | Technology |
52-Week High | $491.22 | $233.89 |
52-Week Low | $205.48 | $113.59 |
Enterprise Value | $27.56B | $10.35B |
Dividend Yield | — | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Paycom Software (PAYC) trades at $211.28, down 1.02% today, with a bullish technical outlook per moving averages but overbought RSI signals. The company reported strong Q2 2026 results, beating EPS estimates with $2.78 versus $2.38 expected, and raised its full-year revenue and EBITDA guidance, driven by AI-driven demand and operational efficiency.
The stock offers growth potential from robust earnings momentum and high profitability margins, but risks include valuation premiums and competitive pressures. Analyst consensus is mixed with a $219.22 price target, suggesting moderate upside from current levels amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
